A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
About this study
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
- Condition
- Diabetes Mellitus, Type 2
- Tested
- AMG 127, Placebo
- Sponsor
- Amgen
Who can join
- Age
- 18 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 75 years
- Study condition: Diabetes Mellitus, Type 2
- Participant must be 18-65 years of age
- Participant must be overtly healthy
- Participant must be 40-75 years of age
- Confirmed diagnoses of T2DM
Exclusion 4
- History of hypotension, syncope, or orthostatic intolerance
- Systolic blood pressure \>140 millimeters of mercury (mmHg) or diastolic blood pressure \>90 mmHg
- Hemoglobin A1c (HbA1c) \>10% within the last 3 months
- Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg
Where
2 sites, 2 recruiting
Translational Clinical Research LLC
Aventura, Florida, United States
Orange County Research Center
Lake Forest, California, United States
Contact
-
Amgen Call Center
866-572-6436 medinfo@amgen.com
Potential match only. Final eligibility is determined by the study team.